By Scott Roberts, HealthDay Reporter
MONDAY, Dec. 22, 2014 (HealthDay News) -- Viekira Pak, a combination of four antiviral drugs -- ombitasvir, paritaprevir, ritonavir and dasabuvir -- has been approved by the U.S. Food and Drug Administration to treat hepatitis C infection, including a major complication, cirrhosis of the liver.
Some 3.2 million Americans are infected with the viral disease, which can lead to complications including reduced liver function, liver failure or liver cancer, the FDA said in a news release. Most infected people have no symptoms before onset of liver damage.
Without proper treatment, 15 percent to 30 percent will develop advanced liver disease known as cirrhosis, the agency said.
The combination pack's safety and effectiveness were evaluated in clinical studies involving more than 2,300 people with chronic hepatitis C, with and without cirrhosis. The most common side effects included fatigue, itching, weakness, lack of energy, nausea and trouble sleeping.
Viekira Pak is marketed by AbbVie Inc., based in North Chicago.
More information
Visit the FDA to learn more.
Copyright © 2014 HealthDay. All rights reserved.
This entry passed through the Full-Text RSS service - if this is your content and you're reading it on someone else's site, please read the FAQ at http://ift.tt/jcXqJW.
Want something else to read? How about 'Grievous Censorship' By The Guardian: Israel, Gaza And The Termination Of Nafeez Ahmed's Blog
from U.S. News - Health http://ift.tt/1zpKnW4
No comments:
Post a Comment